UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000058628
Receipt number R000066558
Scientific Title Verification of the effect of oral intake of base supplements on health checkup values
Date of disclosure of the study information 2025/07/30
Last modified on 2025/07/29 11:30:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

General supplement intake test

Acronym

General supplement intake test

Scientific Title

Verification of the effect of oral intake of base supplements on health checkup values

Scientific Title:Acronym

Testing of base supplements

Region

Japan


Condition

Condition

Healthy volunteer

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Verification of whether taking supplements improves health checkup results

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Health check value

Key secondary outcomes

Experience Survey Results


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Test foods A-1 (1 capsule/day), A-2 (4 tablets/day), and A-3 (4 capsules/day) were taken continuously for 24 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Healthy person

Key exclusion criteria

Those currently undergoing treatment for an illness (including taking medicines), those who need treatment for an illness, or those who are scheduled to undergo treatment in the future, and those who are deemed inappropriate by the principal investigator

Target sample size

654


Research contact person

Name of lead principal investigator

1st name Yoshiharu
Middle name
Last name Matahira

Organization

Sunsho Pharmaceutical Co.,Ltd.

Division name

Research and Development Division

Zip code

418-0019

Address

Innovation Center 12, Nanryo, Fujinomiya, Shizuoka

TEL

0544-25-1484

Email

y.matahira@sunsho.co.jp


Public contact

Name of contact person

1st name Masahiro
Middle name
Last name Kurono

Organization

Sunsho Pharmaceutical Co., Ltd.

Division name

Product Development Section

Zip code

418-0019

Address

Innovation Center 12, Nanryo, Fujinomiya, Shizuoka

TEL

0544-25-1484

Homepage URL


Email

masahiro.kurono@sunsho.co.jp


Sponsor or person

Institute

Sunsho Pharmaceutical Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Sunsho Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Sunsho Pharmaceutical Co., Ltd. Ethics Review Board

Address

1468 Atsuhara, Fuji, Shizuoka

Tel

0545-73-0610

Email

takahiro.fukumoto@sunsho.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 07 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 06 Month 20 Day

Date of IRB

2025 Year 06 Month 23 Day

Anticipated trial start date

2025 Year 08 Month 01 Day

Last follow-up date

2026 Year 05 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 07 Month 29 Day

Last modified on

2025 Year 07 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066558